$RGBP Recently, 4 MY T, brought to the board's at
Post# of 373
Posted On: 12/10/2015 1:55:59 PM
Posted By: 4 MY T
Re: Mysterium #110
A post on the IHub board:
LoveAndLight Member Level Thursday, 12/10/15 12:53:28 PM
Re: None
Post # of 21101
Hello everyone! Just thought I'd share with you some things...
I called in and spoke recently last week with a company rep and through my personal due diligence I found out... Good things must BE happening!
I was told Merck and Eli Lilly have been calling and in contact with Regen. Wasn't told any specifics though... However they must BE interested in something right? Very positive IMO!
Also I was told... patents for NR2F6 Personalized Checkpoint Inhibitor Cancer Immunotherapy development for treatment in cancer patients are gaining a lot of new attention and interest.
I honestly don't know what all this will lead to in the short term future, but obviously there are some great things happening behind the scenes.
Happy to BE on board with Regen/RGBP!
Read More: http://investorshangout.com/post/view?id=3405...z3ustplIZ8
LoveAndLight Member Level Saturday, 12/19/15 11:23:14 PM
Re: None
Post #
22495
of 22506 Go
Regen's and Dr. Lander's new research partner from NCATS & NIH...
Menghang Xia NCATS staff profile:
http://ncats.nih.gov/staff/mxia
Blessings and best wishes,
LoveAndLight smile
We are talking some serious business here!
Menghang Xia leads systems toxicology activities for the Toxicology in the 21st Century (Tox21) initiative at NCATS. Since joining the NIH Chemical Genomics Center, now the NCATS Chemical Genomics Center (NCGC), in 2005, she has played a key leadership role in multiple projects, including Tox21.
Before joining NCGC, Xia identified and validated several targets for drug development at Merck Research Laboratories. smile